Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Matusz-Fisher A"'
Autor:
Patel, Jai N., Robinson, Myra, Jagosky, Megan, Slaughter, Daniel, Arnall, Justin, Jandrisevits, Elizabeth, Matusz-Fisher, Ashley, Atrash, Shebli, Paul, Barry, Bhutani, Manisha, Voorhees, Peter, Usmani, Saad Z.
Publikováno v:
In Clinical Lymphoma, Myeloma and Leukemia March 2021 21(3):188-198
Autor:
Ghosh N; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Charlotte, NC., Matusz-Fisher A; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Charlotte, NC., Bose R; Department of Biostatistics and Data Sciences, Levine Cancer Institute, Atrium Health, Charlotte, NC., Boselli D; Department of Biostatistics and Data Sciences, Levine Cancer Institute, Atrium Health, Charlotte, NC., Magee G; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Charlotte, NC., Chen T; Department of Biostatistics and Data Sciences, Levine Cancer Institute, Atrium Health, Charlotte, NC., Hu B; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Charlotte, NC., Moyo T; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Charlotte, NC., Soni A; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Charlotte, NC., Park S; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Charlotte, NC., Copelan E; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Charlotte, NC., Avalos B; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Charlotte, NC., Symanowski J; Department of Biostatistics and Data Sciences, Levine Cancer Institute, Atrium Health, Charlotte, NC., Raghavan D; Levine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Charlotte, NC., Jacobs R; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Charlotte, NC.
Publikováno v:
JCO oncology practice [JCO Oncol Pract] 2024 Nov 18, pp. OP2400417. Date of Electronic Publication: 2024 Nov 18.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Antoinette R Tan, Ashley Matusz-Fisher
Publikováno v:
Expert opinion on biological therapy. 22(3)
Introduction Human epidermal growth factor receptor 2 (HER2)-positive breast cancers account for approximately 15 to 20% of breast cancer diagnoses. Historically, HER2-positive breast cancers had been associated with poorer prognosis. The addition of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7181a67a42decce6e073cb130f5f0395
https://pubmed.ncbi.nlm.nih.gov/34806498
https://pubmed.ncbi.nlm.nih.gov/34806498
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Annals of Translational Medicine. 10:1031-1031
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da594cbd8161fd788ec258c3d7a25e07
https://doi.org/10.21037/atm-22-1892
https://doi.org/10.21037/atm-22-1892
Autor:
Peter M. Voorhees, Paul Barry, Ami Ndiaye, Issam Hamadeh, Ashley Matusz-Fisher, Manisha Bhutani, Shebli Atrash, Saad Z. Usmani
Publikováno v:
ADVANCES IN CELL AND GENE THERAPY. 4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5220165d76f43a7391eb23d74fdaf0b5
https://doi.org/10.1002/acg2.95
https://doi.org/10.1002/acg2.95
Autor:
Paul Barry, Issam Hamadeh, Saad Z. Usmani, Ashley Matusz Fisher, Maham Ashraf Khan, Shebli Atrash, Jordan Robinson
Publikováno v:
ADVANCES IN CELL AND GENE THERAPY. 4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::05a86eee915b7ebb994ba1a0c07ba31b
https://doi.org/10.1002/acg2.96
https://doi.org/10.1002/acg2.96
Autor:
Ashley Matusz-Fisher, Nilanjan Ghosh, Tommy Chen, Amy Soni, James T. Symanowski, Danielle Boselli, Ryan Jacobs, Bei Hu, Derek Raghavan, Rupali Bose, Steven I. Park, Belinda R. Avalos, Edward A. Copelan, Tamara K. Moyo, Gray Magee
Publikováno v:
Blood. 138:1557-1557
Background: Chronic lymphocytic leukemia (CLL) is one of the most common lymphoid malignancies in adults. Venetoclax, an orally administered B-cell lymphoma 2 (BCL2) inhibitor, is a FDA approved therapy offering durable responses. Due to risk of tumo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f83d6aff159e585683bee0520a26c73
https://doi.org/10.1182/blood-2021-145714
https://doi.org/10.1182/blood-2021-145714